Actress Park Min-young 'Breaks Up'... Park Min-young's Sister 'Resigns'

[Asia Economy Reporter Hwang Junho] Following reports that actress Park Min-young is dating Kang Mo, who is presumed to be the actual owner of Inbiogen, Park Min-young declared her breakup with Kang, and her sister, Park Min-ah, resigned from her position as an outside director of Inbiogen, a company listed on the KOSPI market.

According to the Financial Supervisory Service's electronic disclosure system on the 2nd, Park Min-ah voluntarily resigned from her position as an outside director of Inbiogen on the 29th of last month due to personal reasons. Her resignation came after reports on the 28th of last month that Park Min-young was dating Kang, who is known as the actual owner of Inbiogen. The CEO of the company is Kang Ji-yeon, who is known to be Kang Mo’s sibling.

Park Min-ah is currently a researcher at the Saw Swee Hock School of Public Health at the National University of Singapore, specializing in infectious disease research. Inbiogen appointed Park and Professor Lee from the National University of Singapore as outside directors at the shareholders' meeting on March 29. Professor Lee voluntarily resigned on June 27. Since her appointment, Park attended only one of the seven board meetings held until the end of June. The two outside directors, including Park, received a total of 29 million KRW in compensation during the first half of this year, averaging 14.5 million KRW per person.

After the dating rumors surfaced, Park Min-young appears to be quickly ending her relationship with Kang Mo. On the 29th, one day after the dating rumors were reported, Park Min-young’s agency, Hook Entertainment, stated, "Park Min-young has currently broken up with the person involved in the dating rumors. Furthermore, it is absolutely not true that Park Min-young received significant financial support from the person involved in the rumors," adding, "Her sister, Park Mo, has also expressed her intention to resign as an outside director of Inbiogen."

Meanwhile, Inbiogen primarily operates in shoe manufacturing, sales, and kiosk distribution businesses, and has ventured into the F&B business as a new enterprise. In 2020, the company added new business objectives to its articles of incorporation, including new drug development and vaccine product development and production. In the first half of this year, it recorded sales of 6.3 billion KRW and an operating loss of 2.5 billion KRW.